vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Citi Trends Inc (CTRN). Click either name above to swap in a different company.
Citi Trends Inc is the larger business by last-quarter revenue ($197.1M vs $139.2M, roughly 1.4× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -3.5%, a 39.0% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 10.1%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $767.0K). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -4.3%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Citi Trends, Inc. is an American retail clothing chain selling discounted products targeted primarily at African-American customers.
ADMA vs CTRN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $197.1M |
| Net Profit | $49.4M | $-6.9M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | -3.7% |
| Net Margin | 35.5% | -3.5% |
| Revenue YoY | 18.4% | 10.1% |
| Net Profit YoY | -55.9% | 3.6% |
| EPS (diluted) | $0.20 | $-0.86 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $197.1M | ||
| Q3 25 | $134.2M | $190.8M | ||
| Q2 25 | $122.0M | $201.7M | ||
| Q1 25 | $114.8M | $211.2M | ||
| Q4 24 | $117.5M | $179.1M | ||
| Q3 24 | $119.8M | $176.6M | ||
| Q2 24 | $107.2M | $186.3M | ||
| Q1 24 | $81.9M | $215.2M |
| Q4 25 | $49.4M | $-6.9M | ||
| Q3 25 | $36.4M | $3.8M | ||
| Q2 25 | $34.2M | $871.0K | ||
| Q1 25 | $26.9M | $-14.2M | ||
| Q4 24 | $111.9M | $-7.2M | ||
| Q3 24 | $35.9M | $-18.4M | ||
| Q2 24 | $32.1M | $-3.4M | ||
| Q1 24 | $17.8M | $3.6M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | -3.7% | ||
| Q3 25 | 38.0% | 1.8% | ||
| Q2 25 | 35.1% | 0.2% | ||
| Q1 25 | 30.4% | 0.6% | ||
| Q4 24 | 32.6% | -4.9% | ||
| Q3 24 | 33.1% | -14.1% | ||
| Q2 24 | 36.6% | -3.7% | ||
| Q1 24 | 26.7% | 1.8% |
| Q4 25 | 35.5% | -3.5% | ||
| Q3 25 | 27.1% | 2.0% | ||
| Q2 25 | 28.1% | 0.4% | ||
| Q1 25 | 23.4% | -6.7% | ||
| Q4 24 | 95.2% | -4.0% | ||
| Q3 24 | 30.0% | -10.4% | ||
| Q2 24 | 29.9% | -1.8% | ||
| Q1 24 | 21.7% | 1.7% |
| Q4 25 | $0.20 | $-0.86 | ||
| Q3 25 | $0.15 | $0.46 | ||
| Q2 25 | $0.14 | $0.11 | ||
| Q1 25 | $0.11 | $-1.70 | ||
| Q4 24 | $0.45 | $-0.86 | ||
| Q3 24 | $0.15 | $-2.21 | ||
| Q2 24 | $0.13 | $-0.42 | ||
| Q1 24 | $0.08 | $0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | — |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $107.8M |
| Total Assets | $624.2M | $464.3M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | — | ||
| Q2 24 | $88.2M | — | ||
| Q1 24 | $45.3M | — |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $107.8M | ||
| Q3 25 | $431.2M | $113.2M | ||
| Q2 25 | $398.3M | $108.6M | ||
| Q1 25 | $373.4M | $113.2M | ||
| Q4 24 | $349.0M | $130.3M | ||
| Q3 24 | $231.9M | $136.6M | ||
| Q2 24 | $188.3M | $154.8M | ||
| Q1 24 | $153.7M | $157.7M |
| Q4 25 | $624.2M | $464.3M | ||
| Q3 25 | $568.7M | $457.4M | ||
| Q2 25 | $558.4M | $437.4M | ||
| Q1 25 | $510.6M | $462.8M | ||
| Q4 24 | $488.7M | $467.1M | ||
| Q3 24 | $390.6M | $506.7M | ||
| Q2 24 | $376.4M | $484.1M | ||
| Q1 24 | $350.9M | $518.7M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $8.6M |
| Free Cash FlowOCF − Capex | $34.6M | $767.0K |
| FCF MarginFCF / Revenue | 24.8% | 0.4% |
| Capex IntensityCapex / Revenue | 0.8% | 4.0% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $11.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $8.6M | ||
| Q3 25 | $13.3M | $3.9M | ||
| Q2 25 | $21.1M | $-11.0M | ||
| Q1 25 | $-19.7M | $28.5M | ||
| Q4 24 | $50.2M | $-18.4M | ||
| Q3 24 | $25.0M | $5.6M | ||
| Q2 24 | $45.6M | $-19.6M | ||
| Q1 24 | $-2.2M | $23.3M |
| Q4 25 | $34.6M | $767.0K | ||
| Q3 25 | $-1.1M | $-1.7M | ||
| Q2 25 | $18.7M | $-13.1M | ||
| Q1 25 | $-24.4M | $26.0M | ||
| Q4 24 | $47.5M | $-20.4M | ||
| Q3 24 | $24.0M | $1.7M | ||
| Q2 24 | $43.6M | $-21.2M | ||
| Q1 24 | $-4.6M | $20.0M |
| Q4 25 | 24.8% | 0.4% | ||
| Q3 25 | -0.8% | -0.9% | ||
| Q2 25 | 15.3% | -6.5% | ||
| Q1 25 | -21.2% | 12.3% | ||
| Q4 24 | 40.4% | -11.4% | ||
| Q3 24 | 20.0% | 0.9% | ||
| Q2 24 | 40.7% | -11.4% | ||
| Q1 24 | -5.6% | 9.3% |
| Q4 25 | 0.8% | 4.0% | ||
| Q3 25 | 10.7% | 2.9% | ||
| Q2 25 | 2.0% | 1.0% | ||
| Q1 25 | 4.1% | 1.2% | ||
| Q4 24 | 2.3% | 1.1% | ||
| Q3 24 | 0.9% | 2.2% | ||
| Q2 24 | 1.9% | 0.9% | ||
| Q1 24 | 2.9% | 1.5% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 1.01× | ||
| Q2 25 | 0.62× | -12.59× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | 6.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
CTRN
Segment breakdown not available.
